PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech reported a sharp fall in revenue for the December 2025 quarter at Rs 69.81 lakh, down from Rs 1,441.18 lakh in the same quarter last year — a drop of around 95%. For the nine months ended December 2025, revenue fell to Rs 284.92 lakh from Rs 1,995.18 lakh a year ago, an 86% decline. Profit after tax for the quarter stood at Rs 32.23 lakh versus Rs 77.17 lakh last year, while nine-month PAT slipped to Rs 66.34 lakh from Rs 133.29 lakh. Notably, the core business is now loss-making at the operating level (revenue Rs 69.81 lakh vs expenses Rs 74.67 lakh), with the company staying in profit only because of Rs 37.08 lakh in other income. The statutory auditor (Bipin & Co.) issued an unmodified limited review report.
The dramatic revenue collapse and the fact that operations are now loss-making (with profits propped up by other income) are red flags for shareholders. Unless revenue recovers or cost base is cut further, the stock faces fundamental pressure despite the headline profit still being positive.